• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sirtex Medical

Sirtex Medical begins European launch for microsphere delivery system following EU approval

September 16, 2024 By Sean Whooley

Sirtex Siros microsphere delivery system (1)

Sirtex Medical announced today that it received EU MDR certification to market its SIR-Spheres Y-90 resin microspheres and delivery systems. EU MDR authorization enables Woburn, Massachusetts-based Sirtex to kick off a European launch for its Siros delivery system. Siros offers an intuitive, visual and adaptable solution for physicians to administer SIR-Spheres to liver cancer patients. […]

Filed Under: Drug-Device Combinations, Immunotherapy, Oncology, Regulatory/Compliance Tagged With: Sirtex Medical

Sirtex accepts CDH acquisition offer, moves away from Varian

June 14, 2018 By Sarah Faulkner

Varian to acquire Sirtex

In the ongoing back-and-forth to acquire Sirtex Medical (ASX:SRX), it seems that Varian Medical‘s (NYSE:VAR) $1.2 billion bid just wasn’t enough. Varian said today that it heard from Sirtex that the company’s board couldn’t turn down the $1.41 billion unsolicited offer from China’s CDH Investments. The bid from CDH Investments came in at a 20% premium […]

Filed Under: Featured, Mergers & Acquisitions, Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: CDH Investments, Sirtex Medical, Varian Medical Systems

Varian stands on $1.28B offer for Sirtex

May 22, 2018 By Sarah Faulkner

Varian to acquire Sirtex

Varian Medical (NYSE:VAR) said today that it stands behind its initial $1.28 billion bid to acquire Sirtex Medical (ASX:SRX) in the wake of a $1.41 billion counter offer from China’s CDH Investments. The unsolicited bid from CDH Investments came in at a 20% premium on Varian’s A$28-per-share offer, prompting Sirtex to reconsider a merger that already […]

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: CDH Investments, Sirtex Medical, Varian Medical Systems

China’s CDH Investments counters Varian with unsolicited $1.4B bid for Sirtex

May 4, 2018 By Brad Perriello

Varian to acquire Sirtex

Sirtex Medical (ASX:SRX) said today that it’s fielding an unsolicited, $1.41 billion counter-offer from China’s CDH Investments that trumps a previous, $1.28 billion bid from Varian Medical (NYSE:VAR) that’s already won approval from U.S. and German regulators. CDH’s A$33.60-per-share offer is a 20% premium on Varian’s initial A$28-per-share offer and prompted Sirtex to seek to scuttle a […]

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology Tagged With: CDH Investments, Sirtex Medical, Varian Medical Systems

U.S., German antitrust authorities clear Varian’s $1.3B Sirtex buyout

March 15, 2018 By Sarah Faulkner

Varian to acquire Sirtex

U.S. antitrust authorities and the German Federal Cartel Office cleared Varian Medical‘s (NYSE:VAR) $1.3B proposed buyout of Sirtex Medical (ASX:SRX), Varian reported today. The companies first announced that they inked a deal for Varian to acquire all of Sirtex’s outstanding shares in January this year. The transaction is slated to close in late May. Sirtex shareholders […]

Filed Under: Featured, Mergers & Acquisitions, Oncology, Wall Street Beat Tagged With: Sirtex Medical, Varian Medical Systems

Varian Medical to pay $1.3B for Sirtex

January 30, 2018 By Brad Perriello

Varian to acquire Sirtex

Varian Medical (NYSE:VAR) yesterday said it agreed to pay nearly $1.3 billion for Australia’s Sirtex Medical (ASX:SRX) and its anti-cancer microspheres. The A$28-per-share offer, which values Sirtex at A$1.59 billion (about $1.28 billion), is slated to close in late May, Palo Alto, Calif.-based Varian said. It’s part of a bid to broaden that company’s oncology portfolio. Sirtex makes […]

Filed Under: Featured, Mergers & Acquisitions, Oncology, Radiosurgery, Wall Street Beat Tagged With: Sirtex Medical, Varian Medical Systems

Sirtex swings to a loss after ‘challenging’ year

August 23, 2017 By Sarah Faulkner

Sirtex Medical

Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before. Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Sirtex Medical

Sirtex shares jump on restructuring plan, 15% headcount reduction

June 28, 2017 By Fink Densford

Sirtex Medical

Sirtex Medical (ASX:SRX) saw shares jump today after revealing plans for a major restructuring as the company looks to cut its headcount and focus on its “profitable core business.” The company said it underwent an “extensive review of the business” to identify where it could improve efficiencies. The review led to an initial $7 million […]

Filed Under: Business/Financial News, Featured Tagged With: Sirtex Medical

Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial

June 5, 2017 By Sarah Faulkner

Sirtex Medical

Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial. The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib. Data from the 360-patient trial […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Sirtex Medical

Sirtex Medical ticks up after Aussie court bars injunction

May 30, 2017 By Brad Perriello

Sirtex Medical

Sirtex Medical (ASX:SRX) said yesterday that Australia’s Federal Court denied a shareholders bid for an injunction barring its pending share buyback. The shareholders lawsuit accuses Sirtex of breaching continuous disclosure obligations and engaged in misleading and deceptive conduct, alleging that its guidance for double-digit sales growth “has no reasonable grounds.” Yesterday the Australian company said the Federal Court dismissal of the shareholders’ injunction […]

Filed Under: Legal News, Oncology, Wall Street Beat Tagged With: Sirtex Medical

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS